CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Annexon Expands Vonaprument Phase 3 Trial With Month 24 Dual Primary Endpoint

Phase 3VonaprumentNeutral
AI Analysis

Summary

Annexon announced an expansion of its Phase 3 trial for Vonaprument, adding Month 24 as a dual primary endpoint.

Clinical Trial Data

Phase

Phase 3

Importance:5/10
Sentiment:
0.00
Phase 3trial expansionprimary endpoint
Related Companies

Read the original article

Published by yahoo_finance on August 12, 2026 10:49 AM

Read Original